IL6 and melanoma: LAG-3 was expressed at higher levels on plasmacytoid dendritic cells (pDCs) compared to effector T-cells or regulatory T-cells.28 Furthermore, the interaction between LAG-3 on human pDCs and MHC Class II on melanoma cells resulted in the activation of LAG-3+ pDCs and secretion of the cytokine IL-6, suggesting a role for LAG-3+ pDCs in driving immunosuppression in the melanoma microenvironment.29 These data highlight the need for further research into LAG-3 expression on dendritic cells and the potential role of this population in response or resistance to anti-LAG-3 immunotherapies.